Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2452473 for Symptom Management in Prostate Cancer
NCT02499497Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY2452473 in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Feb 2016; status: completed.
02
Drugs
LY2452473
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02499497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499497.